505 related articles for article (PubMed ID: 17532766)
21. Rituximab in the treatment of autoimmune haematological disorders.
Garvey B
Br J Haematol; 2008 Apr; 141(2):149-69. PubMed ID: 18318765
[TBL] [Abstract][Full Text] [Related]
22. Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias.
Rao A; Kelly M; Musselman M; Ramadas J; Wilson D; Grossman W; Shenoy S
Pediatr Blood Cancer; 2008 Apr; 50(4):822-5. PubMed ID: 17570702
[TBL] [Abstract][Full Text] [Related]
23. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab.
Schweizer C; Reu FJ; Ho AD; Hensel M
Ann Hematol; 2007 Oct; 86(10):711-7. PubMed ID: 17622529
[TBL] [Abstract][Full Text] [Related]
24. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome.
Shanafelt TD; Madueme HL; Wolf RC; Tefferi A
Mayo Clin Proc; 2003 Nov; 78(11):1340-6. PubMed ID: 14601692
[TBL] [Abstract][Full Text] [Related]
25. Successful anti-CD20 monoclonal antibody treatment of severe autoimmune hemolytic anemia due to warm reactive IgM autoantibody in a child with common variable immunodeficiency.
Wakim M; Shah A; Arndt PA; Garratty G; Weinberg K; Hofstra T; Church J
Am J Hematol; 2004 Jun; 76(2):152-5. PubMed ID: 15164382
[TBL] [Abstract][Full Text] [Related]
26. Rituximab-based immunosuppression for autoimmune haemolytic anaemia in infants.
Svahn J; Fioredda F; Calvillo M; Molinari AC; Micalizzi C; Banov L; Schmidt M; Caprino D; Marinelli D; Gallisai D; Dufour C
Br J Haematol; 2009 Apr; 145(1):96-100. PubMed ID: 19208098
[TBL] [Abstract][Full Text] [Related]
27. [Successful treatment with rituximab in a patient with refractory mixed-type autoimmune hemolytic anemia].
Ono K; Sato T; Iyama S; Tatekoshi A; Hashimoto A; Kamihara Y; Horiguchi H; Kikuchi S; Takada K; Hayashi T; Miyanishi K; Sato Y; Takimoto R; Kobune M; Kato J
Rinsho Ketsueki; 2013 Nov; 54(11):2053-5. PubMed ID: 24305538
[TBL] [Abstract][Full Text] [Related]
28. [Autoimmune hemolytic anemia].
Berentsen S; Sundic T; Hervig T; Tjønnfjord GE
Tidsskr Nor Laegeforen; 2009 Nov; 129(21):2226-31. PubMed ID: 19898570
[TBL] [Abstract][Full Text] [Related]
29. Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults.
Provan D; Butler T; Evangelista ML; Amadori S; Newland AC; Stasi R
Haematologica; 2007 Dec; 92(12):1695-8. PubMed ID: 18055995
[TBL] [Abstract][Full Text] [Related]
30. Direct antiglobulin test reactive with complement only in warm type autoimmune hemolytic anemia.
Shvidel L; Shtalrid M; Duek A; Haran M; Berrebi A; Sigler E
Int J Lab Hematol; 2008 Dec; 30(6):494-8. PubMed ID: 18983301
[TBL] [Abstract][Full Text] [Related]
31. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients.
Peñalver FJ; Jiménez-Yuste V; Almagro M; Alvarez-Larrán A; Rodríguez L; Casado M; Gallur L; Giraldo P; Hernández R; Menor D; Rodríguez MJ; Caballero D; González R; Mayans J; Millán I; Cabrera JR;
Ann Hematol; 2006 Jun; 85(6):400-6. PubMed ID: 16550390
[TBL] [Abstract][Full Text] [Related]
32. Treatment of refractory fludarabine induced autoimmune haemolytic with the anti-CD20 monoclonal antibody rituximab.
Swords R; Nolan A; Fay M; Quinn J; O'Donnell R; Murphy PT
Clin Lab Haematol; 2006 Feb; 28(1):57-9. PubMed ID: 16430461
[TBL] [Abstract][Full Text] [Related]
33. Consolidation treatment with rituximab induces complete and persistent remission of mixed type Evans syndrome.
Rodella E; Pacquola E; Bianchini E; Ramazzina E; Paolini R
Blood Coagul Fibrinolysis; 2008 Jun; 19(4):315-8. PubMed ID: 18469554
[TBL] [Abstract][Full Text] [Related]
34. [Anti-CD20 monoclonal antibody for the treatment of refractory autoimmune hemolytic anemia].
Wang L; Xu W; Li JY; Xie XY; Sheng RL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Apr; 15(2):425-8. PubMed ID: 17493362
[TBL] [Abstract][Full Text] [Related]
35. Prompt response to rituximab of severe hemolytic anemia with both cold and warm autoantibodies.
Webster D; Ritchie B; Mant MJ
Am J Hematol; 2004 Apr; 75(4):258-9. PubMed ID: 15054824
[TBL] [Abstract][Full Text] [Related]
36. Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus.
Perrotta S; Locatelli F; La Manna A; Cennamo L; De Stefano P; Nobili B
Br J Haematol; 2002 Feb; 116(2):465-7. PubMed ID: 11841453
[TBL] [Abstract][Full Text] [Related]
37. Success of anti-CD20 monoclonal antibody treatment for severe autoimmune hemolytic anemia caused by warm-reactive immunoglobulin A, immunoglobulin G, and immunoglobulin M autoantibodies in a child: a case report.
Ajmi H; Mabrouk S; Hassayoun S; Regaieg H; Tfifha M; Jalel C; Skouri H; Zouari N; Abroug S
J Med Case Rep; 2017 Nov; 11(1):321. PubMed ID: 29132419
[TBL] [Abstract][Full Text] [Related]
38. Rituximab is an effective and safe treatment of relapse in elderly patients with resistant warm AIHA.
Laribi K; Bolle D; Ghnaya H; Sandu A; Besançon A; Denizon N; Truong C; Pineau-Vincent F; de Materre AB
Ann Hematol; 2016 Apr; 95(5):765-9. PubMed ID: 26858026
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studies.
Reynaud Q; Durieu I; Dutertre M; Ledochowski S; Durupt S; Michallet AS; Vital-Durand D; Lega JC
Autoimmun Rev; 2015 Apr; 14(4):304-13. PubMed ID: 25497766
[TBL] [Abstract][Full Text] [Related]
40. [The long-term efficacy and safety of rituximab combined with cyclophosphamide in treatment of seven patients with refractory and recurrent autoimmune hemolytic anemia].
Liu H; Xing LM; Wang HQ; Wu YH; Qu W; Liang Y; Wang GJ; Song J; Wang XM; Guan J; Li LJ; Fu R; Shao ZH
Zhonghua Nei Ke Za Zhi; 2012 Jun; 51(6):456-9. PubMed ID: 22943757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
